PRIMA BIOMED SECURES KEY CANCER PATENT IN U.S.Prima Biomed Limited (ASX ASXSee: Australian Stock Exchange : PRR PRR Pennsylvania Railroad PRR Prairie (street suffix) PRR Production Readiness Review PRR Policy Research Report (Worldbank) PRR Pattern Recognition Receptor (immunology) ) has been granted a US patent for its subsidiary Cancer Vac Limited. Cancer Vac is developing a treatment for cancer based on inducing a patient's own immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. to attack tumors. The granted United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. Patent protects additional cancer antigens which Cancer Vac can use in the commercialization of its immunotherapy program. This latest Patent will remain in force until 2018. Cancer Vac has exclusively licensed four "families" of patent applications from the Austin Research Institute in Melbourne. Each family consists of applications in major countries, including the US, Europe, Japan, Australia and Canada and are mostly at advanced stages of examination for compliance with respective National Patent Law. A number of Patents, including the Patent announced today, have progressed to granted, enforceable Patents. The Patent referred to in this announcement is from Family 4. Family 1 is directed to the mannan man·nan n. Any of a group of plant polysaccharides that are polymers of mannose. [mann(ose) + -an2.] adjuvant adjuvant /ad·ju·vant/ (aj?dbobr-vant) (a-joo´vant) 1. assisting or aiding. 2. a substance that aids another, such as an auxiliary remedy. 3. - antigen conjugate conjugate /con·ju·gate/ (kon´jdbobr-gat) 1. paired, or equally coupled; working in unison. 2. a conjugate diameter of the pelvic inlet; used alone usually to denote the true conjugate diameter; see , used to prime the immune system's dendritic cells dendritic cell n. 1. A cell that has branching processes. 2. Any of the cells in the neural crest of the embryonic ectoderm having extensive processes and developing early as producers of melanin. . Family 2 is directed to cancer antigens believed to be capable of stimulating anti-cancer immune responses. These are synthetic proteins that are based on MUC MUC Mount Union College (Ohio) MUC Multi User Chat MUC Message Understanding Conference MUC Montreal Urban Community MUC Malaspina University College (Canada) 1. Patents from families 1 and 2 have already been granted in Australia. Family 3 is directed at the procedure and immune cell product used by Cancer Vac to deliver its immunotherapy. Family 4, like family 2, is directed to cancer antigens, specifically other immunogenic im·mu·no·gen·ic adj. Producing an immune response. immunogenic producing immunity; evoking an immune response. portions of MUC1. This family has been filed as national Patent applications in Australia, Canada, Europe and Japan, and is now granted in the US. The initial stage of the Cancer Vac Phase I trial has been completed, meeting all of the study endpoints for safety and immune responses. In the study, all participants receiving the Cancer Vac immunotherapy generated immune responses that recognized the MUC 1 cancer antigen, with the treatment being well tolerated by all patients. The original Phase I study has been extended to recruit new patients and to continue treatment in a small number of the original patients to enable the company to evaluate a streamlined treatment program and the effect of ongoing immunotherapy. Cancer Vac is currently preparing for a Phase II trial that will be designed around the enlarged and extended results of the Phase I trial. The granting of this Patent is significant for Cancer Vac in further strengthening the IP portfolio and protection around the Cancer Vac suite of technologies. This also significantly strengthens Cancer Vac's commercialization strategy which is currently progressing. The Cancer Vac immunotherapy involves collecting blood from a patient, extracting a special type of white blood cell from the blood and then "loading" the isolated cells with a vaccine (comprising a mixture of a cancer antigen and a sugar that is used to enhance uptake of the vaccine). These primed cells are then re-administered to the patient to stimulate a specific immune response to the cancer antigen(s) contained in the vaccine. The extracted cells are known as dendritic cells (DCs), a class of immune cells known to play a pivotal role in starting an immune response. About Cancer Vac Limited Cancer Vac is a subsidiary of Prima Biomed Limited (65% owned). The company is focussed on delivering better health outcomes for cancer patients through the development of new approaches to cancer immunotherapy Cancer immunotherapy is the use of the immune system to reject cancer. The main premise is stimulating the patient's immune system to attack the malignant tumor cells that are responsible for the disease. . Cancer Vac is developing immunotherapies based on effective Dendritic Cell priming. About Prima Biomed Based in Melbourne, Prima Biomed (ASX: PRR) is a biotechnology company with a focus in developing and commercializing technology arising from the field of immunology and cancer immunotherapy that shows potential for commercial returns within three to four years. Prima Biomed holds first and last rights over such technologies from the Austin Research Institute. For more information, visit www.primabiomed.com/au. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion